Table.

Level of agreement to recommend pancreatic cancer screening for various combinations of family history and genetic profile. The percentages represent the proportion of international experts (among 49 voting participants) in the CAPS Consortium who agreed with screening for the respective combination⁵. Blank boxes indicate no vote was reported for the combination. Color coding reflects the strength of support for screening (green ≥75%; yellow- 50–74%; red - <50%). FDR, first degree relative. Adapted with permission¹⁶.

Number of affected relatives
	None	1		2		≥3
		1 FDR	No FDR	≥1 FDR	No FDR	≥1 FDR	No FDR
No germline mutation	No	No	No	Yes (92% if 2 FDRs and 78% if 1 FDR)	No 25%	Yes 92%	---
BRCA1	---	Indeterminate 69%	---	Yes 78%	Indeterminate 69%	Yes 78%	---
BRCA2	Indeterminate 51%	Yes 86%	---	Yes 90%	Yes 90%	Yes 90%	---
PALB2	No	Yes 78%	---	Yes 78%	---	Yes 78%	---
STK11	Yes 96%	Yes 96%	Yes 96%	Yes 96%	Yes 96%	Yes 96%	Yes 96%
CDKN2A	Indeterminate 57%	Yes 88%	Indeterminate 57%	Yes 88%	Indeterminate 57%	Yes 88%	Indeterminate 57%
Lynch syndrome*	No	Yes 88%	No 44%	Yes 88%	Indeterminate 53%	Yes 88%	Indeterminate 53%

^*Associated with MLH1, MSH2, MSH6, or PMS2 gene mutations.